Objectives: To evaluate the effi cacy and tolerability of ipilimumab in an Australian clinical setting, and to assess the association of response with melanoma subtype, BRAF mutation status, absolute lymphocyte count and incidence of serious immune-related adverse events (AEs).
A ustralia has the highest incidence of melanoma in the world; melanoma is the fourth most common form of cancer in Australia and the most common cancer in young Australians aged 15-39 years. 1 While surgery remains the mainstay of treatment for early stage melanomas, there have been limited treatment options for more advanced disease and, historically, 5-year survival was less than 15%. 2 Ipilimumab (Yervoy, Bristol-Myers Squibb) is a fully humanised monoclonal antibody directed against the cytotoxic T lymphocyte antigen 4 and the fi rst treatment to demonstrate a survival benefi t in advanced and metastatic disease (see Appendix 1 online at mja.com.au for a summary of published data). Pivotal studies of ipilimumab at 3 mg/kg in relapsed disease and 10 mg/kg in untreated disease demonstrated signifi cant overall survival (OS) advantage compared with comparative arms (ipilimumab 3 mg/kg v vaccine: median OS, 10.1 v 6.4 months; hazard ratio for death, 0.66; P = 0.003; 3 and 10 mg/kg plus dacarbazine v dacarbazine alone: median OS, 11.2 v 9.1 months; hazard ratio for death, 0.72; P < 0.001 4 ). Ipilimumab has demonstrated clinical activity independent of negative prognostic markers (age, M stage or response to prior systemic therapy), offering a novel treatment to patients with poor prognosis. 5 Immune-related adverse events (AEs) are frequently reported in clinical trials with serious events (grade у 3) reported in 10%-56% of patients. 3,4,6,7 3,4,6,7 However, with growing experience, the management of immune-related AEs has improved considerably and established protocols are widely available. 8 Incidence of immune-related AEs and changes in lymphocyte count, presumably refl ecting an immune response to therapy, have been reported to correlate with improved responses and increased survival. 7,9,10 7,9,10 Ipilimumab was registered in Australia by the Therapeutic Goods Administration (TGA) in July 2011 for the treatment (monotherapy at 3 mg/ kg) of unresectable or metastatic melanoma in patients who have progressed through or are intolerant to prior therapy. 11 11 The Pharmaceutical Benefi ts Advisory Committee (PBAC) exhibited caution in recommending ipilimumab for inclusion in the Pharmaceutical Benefi ts Scheme (PBS) due to uncertainty surrounding clinical benefi t and cost-effectiveness in the clinical setting. 12 12 The PBAC public summary document stated that with limited sensitivity analyses conducted on survival data, a small change in the magnitude of any predicted benefi t may signifi cantly change the incremental benefi t and cost-effectiveness of this already expensive agent; basecase incremental cost per qualityadjusted life-year gained is estimated to be between $45 000-$75 000. 12 12 Thus, the subsequent positive recommendation for PBS listing requires ongoing data collection to determine whether the survival benefi t modelled in the PBAC submission (and therefore the cost-effectiveness) can be realised in Australian clinical practice.
Of available published data (see Appendix 1 online at mja.com.au), all except two studies 7,9 7,9 are from the clinical trial setting. Supportive data from clinical practice settings, and more specifi cally from within Australia, are lacking. Our primary aim was to provide survival and toxicity outcomes data for Australian melanoma patients treated with ipilimumab in an Australian clinical practice setting. Secondary aims included the investigation of potential relationships between response and melanoma subtype, BRAF mutation status, absolute lymphocyte count (ALC) and immunerelated AE.
Methods

Study design
We conducted a retrospective review of all patient records over a specifi ed time. Ethics approval was obtained from the Peter MacCallum Cancer Centre Divisional Review Panel and the study was conducted according to the National Health and Medical Research Council National Statement on Ethical Conduct in Human Research (http://www.nhmrc.gov.au/guidelines/ publications/e72).
Patient population
Patients who commenced ipilimumab therapy between July 2010 (fi rst patient treatment) and April 2012 were identifi ed from hospital pharmacy dispensing records. Patients who received at least one dose of ipilimumab were included in the analysis. Patients were enrolled in an access program that enabled access to ipilimumab before TGA registration for patients, with the following eligibility criteria: a histologically confi rmed diagnosis of unresectable (stage III) or metastatic (stage IV) cutaneous, uveal or mucosal melanoma; failure or intolerance to at least one prior treatment; aged у 16 years; and Eastern Cooperative Oncology Group (ECOG) performance status of ഛ 2. According to local protocol, patients received ipilimumab at a dose of 3 mg/kg every 3 weeks for a total of four doses with reinduction offered to patients whose disease had progressed following either stable disease of у 3 months duration or an initial objective response.
Data collection
The medical records of eligible patients were audited to retrieve the following patient-and disease-related factors: melanoma subtype and stage, presence of brain metastasis, lactate dehydrogenase (LDH), BRAF mutation status in exon 15 (BRAF-MT: mutant; BRAF-WT: wild type), past treatments, ECOG performance status, age and sex. Treatment-related information including AEs (serious AE defi ned as у grade 3), ALC (high ALC defi ned as > 1 10 9 /L), date of progression, and reason for cessation of ipilimumab (progressive disease, AE, death) were also collected. Patients were routinely reviewed every 3 weeks during treatment and every 4-6 weeks during surveillance. Radiological imaging was generally performed 6-8 weeks after induction and at least 8-weekly thereafter; however, a recognised limitation of the retrospective study design was an inability to ensure consistent radiological intervals. At each review, clinicians documented tolerability with standard reference to the United States Common terminology criteria for adverse events. 13 13
Data analysis
Data were analysed using Stata version 12.0 (StataCorp). Survival end points were defi ned from the time of fi rst ipilimumab dose until death in the case of overall survival; or on retrospective review of radiology reports or clinical notes suggesting progression or death, in the case of progression-free survival (PFS). For patients eligible for reinduction, a second PFS was calculated from the date of fi rst reinduction dose of ipilimumab. Survival curves for OS and PFS were generated using the Kaplan-Meier method and compared using the log-rank test. For all statistical tests, a threshold of P < 0.05 was used to defi ne signifi cance. 
Effi cacy
Median OS was 9.6 months (95% CI, 6.6-12.4), and median PFS was 3.0 months (95% CI, 2.7-3.4) (Box 1). The 1-and 2-year survival rates were 42% (95% CI, 32%-52%) and 18% (95% CI, 9%-30%), respectively. There were no non-melanoma-related deaths. Subgroup survival analysis is presented in Box 1. OS was similar for patients with and without brain meta stasis (median OS, 9.3 and 10.6 months, respectively; log-rank test, P = 0.91), and PFS following reinduction therapy was signifi cantly greater than PFS for the population as a whole (3.6 months: 95% CI, 3.6-undefi ned [upper limit not yet reached for patients receiving у 2 reinduction ipilimumab doses] v 3 months: 95% CI, 2.7-3.4; P = 0.002). Patients with mucosal and uveal melanoma had reduced OS compared with those with cutaneous melanoma (5.8, 5.7 and 11.7 months, respectively), although this was not a statistically signifi cant fi nding, likely due to small subset numbers (Box 2). PFS was similar across all groups (Box 2). Despite apparent numerical differences in OS by BRAF mutation status and incidence of serious immune-related AEs, small patient numbers resulted in wide confi dence intervals and signifi cance was not demonstrated. High ALC measured before or during ipilimumab induction was associated with an increased PFS (P ഛ 0.005) and numerically superior OS (P > 0.15).
Adverse events
Eighteen patients (17%) experienced a serious AE, with one patient experiencing two serious AEs (Box 1 and Box 3). Seven patients (7%) failed to complete induction due to an AE: diarrhoea/colitis (2), pruritus/rash (2), pituitary failure (1), myasthenia gravis (1) and hepatitis (1). Two patients died due to a treatment-related AE: autoimmune hypophysitis following the fourth dose of ipilimumab (1), and severe diarrhoea/colitis complicated by sepsis following the third dose of ipilimumab.
Discussion
Median OS (9.6 months) and 1-year OS (42%) exceeded proposed benchmark survival targets of 6.5 months for median OS and 25% for 1-year OS from a previous meta-analysis of second-line melanoma treatments. 14 14 Survival outcomes were similar to those reported in the MDX010-20 study (median OS, 10.1 months) 3 and in ipilimumab access schemes using a 10 mg/ kg dosing regimen (median OS, 7.2-9 months). 7,9 7,9 Median PFS (3.0 months) was also similar to the 2.9 months and 2.6-4.3 months found in the MDX010-20 and access scheme studies, respectively. 3,7,9 3,7,9 With just under half of the study population (44/104) having brain metastasis at baseline, there was no difference in OS compared with patients without brain metastasis, suggesting that ipilimumab is an effective treatment option in both clinical situations. Encouragingly, PFS for patients undergoing reinduction therapy was similar to that seen following induction therapy, affording patients an efficacious subsequent treatment option and correlating with fi ndings from recently published work extending on the MDX010-20 study. Although statistical signifi cance is limited by the small number of patients with uveal (n = 11) and mucosal (n = 8) melanomas, there were some observed differences in survival data (Box 1) compared with the more prevalent cutaneous melanoma (n = 79). Trends demonstrated that future investigation of the shorter survival seen in the non-cutaneous subgroups may be warranted. The similar PFS but lower OS may refl ect the different behaviour of the disease or the lack of subsequent treatment options compared with patients with cutaneous melanoma. The latter is unlikely in our patient cohort, where most patients (> 80%) with progressive disease following ipilimumab treatment were palliated (regardless of melanoma subtype) and not receiving subsequent therapy. Other explanatory factors may include the greater proportion of patients with uveal melanoma with widespread disease (M1c, 100%), and greater baseline tumour load (elevated LDH, 82%).
Raised ALC was highly correlated with prolonged PFS; however, although a trend was observed, the association with improved OS as shown in previous studies was not evident. 7,9 7,9 There was a lower incidence of any immune-related AEs in our study (53/104, 51%) compared with the MDX010-20 study (80/131, 61%) . 3 However, this is likely to refl ect poor documentation of low-grade AEs in the routine clinical setting compared with the highly regulated clinical trial setting with rigorous reporting requirements. When considering only serious immune-related AEs, assumed to be more accurately documented, incidence was more closely aligned: 14% (15/104) of patients in the present study compared with 15% (19/131) in the MDX010-20 study. We report similar incidence of overall skin immune-related AEs (41/104, 39% v 57/131, 44%), grade 3-4 skin immunerelated AEs (3/104, 3% v 3/131, 2%) and grade 3-4 diarrhoea/colitis (8/104, 8% v 13/131, 10%). The incidence of treatment-related deaths (grade 5 AE) was comparable, with 2% (2/104) and 3% (4/131) treatment-related mortality rates reported in the current and MDX010-20 studies, respectively.
We reported the clinical details pertaining to the rare and serious ipilimumab AEs experienced by our patients, including two grade 5 events. One patient who had been successfully managed with high-dose steroids for grade 4 diarrhoea/colitis underwent surgical excision of brain metastases. The patient developed colonic microperforation and sepsis, and died, after the steroid dose was tapered postoperatively. The problem of rebound symptoms is well recognised and, consequently, guidelines recommend a prolonged steroid taper over 45-60 days. 8 This case highlights the importance of proper communication to patients and between treating teams. Two patients experienced serious autoimmune hypophysitis, with one subsequent death. The death was a result of delayed recognition of symptoms with an initial working diagnosis of lithium toxicity delaying steroid administration. In the second patient, symptoms developed 1 month after induction therapy. Earlier recognition and treatment with oral steroids and hormone replacement resulted in both a symptomatic and biochemical response, and the patient has maintained a sustained melanoma response to therapy. A single case of grade 3 pituitary failure was attributed to disease progression when magnetic resonance imaging scans unexpectedly demonstrated the presence of extensive bone metastases involving the pituitary fossa. One patient experienced myasthenia gravis, a rare (< 1% incidence) immune-related AE associated with ipilimumab. The 
